"The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
The FDA initially appr"...
- Patient Information:
Details with Side Effects
In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.
- LUPRON (leuprolide acetate injection) INJECTION is contraindicated in patients known to be hypersensitive to GnRH, GnRH agonist analogs or any of the excipients in LUPRON (leuprolide acetate injection) INJECTION: Reports of anaphylactic reactions to GnRH agonist analogs have been reported in the medical literature.
- LUPRON (leuprolide acetate injection) is contraindicated in women who are or may become pregnant while receiving the drug. LUPRON (leuprolide acetate injection) may cause fetal harm when administered to a pregnant woman. Therefore, the possibility exists that spontaneous abortion may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking any formulation of LUPRON (leuprolide acetate injection) , the patient should be apprised of the potential hazard to the fetus.
Last reviewed on RxList: 3/3/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Lupron Information
Lupron - User Reviews
Lupron User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.